Changes

m
no edit summary
Line 1: Line 1: −
'''Table 1 - Clinically significant copy number alterations and regions of loss of heterozygosity in breast cancer''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics.
+
'''Table 1 - Clinically significant copy number alterations and regions of loss of heterozygosity in breast cancer.''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics.
 
{| class="wikitable"
 
{| class="wikitable"
 
|'''Alteration'''
 
|'''Alteration'''
 
|'''Relevant Gene(s)'''
 
|'''Relevant Gene(s)'''
|'''CGC Evidence Level'''
+
|'''CGC Evidence Level'''
 
|'''Subgroup Association(s)'''
 
|'''Subgroup Association(s)'''
 
|-
 
|-
Line 71: Line 71:  
|METABRIC IntClust1, ER Positive
 
|METABRIC IntClust1, ER Positive
 
|}
 
|}
Abbreviations: TNBC, triple negative breast cancer.
+
† See table below Table 2 for CGC Evidence levels
    +
Abbreviations: TNBC, triple negative breast cancer; LOH, loss of heterozygosity.
   −
'''Table 2 - Major clinically significant genes associated with somatic sequence alterations in breast cancer''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics.
+
'''Table 2 - Major clinically significant genes associated with somatic sequence alterations in breast cancer.''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics.
 
{| class="wikitable"
 
{| class="wikitable"
 
|'''Gene(s)'''
 
|'''Gene(s)'''
|'''CGC Evidence Level'''
+
|'''CGC Evidence Level'''
 
|'''Clinical Significance and Subgroup Association(s)'''
 
|'''Clinical Significance and Subgroup Association(s)'''
 
|'''Therapy Implication(s)'''
 
|'''Therapy Implication(s)'''
Line 234: Line 235:  
Abbreviations: BC, breast cancer. TNBC, triple negative breast cancer.
 
Abbreviations: BC, breast cancer. TNBC, triple negative breast cancer.
   −
'''Cancer Genomics Consortium Levels of Evidence'''
+
'''Cancer Genomics Consortium Levels of Evidence'''
 
{| class="wikitable"
 
{| class="wikitable"
 
|'''Tier'''
 
|'''Tier'''
Line 258: Line 259:       −
'''Table 3 - Genes with known hereditary risk associations in breast cancer''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics.
+
'''Table 3 - Genes with known hereditary risk associations in breast cancer.''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics.
 
{| class="wikitable"
 
{| class="wikitable"
 
|'''Gene'''
 
|'''Gene'''